Search results
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 1 day agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 1 day agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 19 hours agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 23 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 6 hours agoRelease Date: May 02, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moderna Inc (NASDAQ:MRNA) reported ...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 23 hours agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Cancer vaccines are having a renaissance
Technology Review· 6 hours agoPersonalized cancer vaccines like the ones Moderna and BioNTech are developing are tailored to each patient’s particular cancer. Together these neoantigens form a kind of ...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 1 day agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
J.P. Morgan downgrades Metagenomi over Moderna deal termination (NASDAQ:MGX)
Seeking Alpha· 19 hours agoJ.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 22 hours agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
